Johnson & Johnson (NYSE:JNJ) Shares Sold by Integrated Advisors Network LLC

Integrated Advisors Network LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 17.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 27,231 shares of the company's stock after selling 5,566 shares during the period. Integrated Advisors Network LLC's holdings in Johnson & Johnson were worth $3,938,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. MRP Capital Investments LLC boosted its stake in shares of Johnson & Johnson by 4.1% in the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after buying an additional 65 shares during the last quarter. Syverson Strege & Co lifted its position in Johnson & Johnson by 4.9% during the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock valued at $202,000 after purchasing an additional 65 shares in the last quarter. Werba Rubin Papier Wealth Management lifted its position in Johnson & Johnson by 3.3% during the fourth quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock valued at $301,000 after purchasing an additional 66 shares in the last quarter. Denali Advisors LLC lifted its position in Johnson & Johnson by 1.3% during the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock valued at $742,000 after purchasing an additional 67 shares in the last quarter. Finally, Sage Mountain Advisors LLC lifted its position in Johnson & Johnson by 0.5% during the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock valued at $2,106,000 after purchasing an additional 67 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on JNJ shares. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Barclays decreased their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Trading Up 0.2%

JNJ traded up $0.37 on Thursday, hitting $152.80. The company had a trading volume of 2,205,755 shares, compared to its average volume of 7,930,565. The business's fifty day simple moving average is $154.63 and its 200 day simple moving average is $153.64. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market cap of $367.65 billion, a PE ratio of 22.99, a PEG ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.40%. Johnson & Johnson's payout ratio is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.